Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Cash from Financing Activities: 2019-2024

Historic Cash from Financing Activities for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $337.2 million.

  • 4D Molecular Therapeutics' Cash from Financing Activities fell 79.58% to $116,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year decrease of 94.57%. This contributed to the annual value of $337.2 million for FY2024, which is 115.04% up from last year.
  • 4D Molecular Therapeutics' Cash from Financing Activities amounted to $337.2 million in FY2024, which was up 115.04% from $156.8 million recorded in FY2023.
  • 4D Molecular Therapeutics' Cash from Financing Activities' 5-year high stood at $337.2 million during FY2024, with a 5-year trough of $3.1 million in FY2022.
  • In the last 3 years, 4D Molecular Therapeutics' Cash from Financing Activities had a median value of $156.8 million in 2023 and averaged $165.7 million.
  • In the last 5 years, 4D Molecular Therapeutics' Cash from Financing Activities soared by 12,809.93% in 2020 and then plummeted by 97.39% in 2022.
  • 4D Molecular Therapeutics' Cash from Financing Activities (Yearly) stood at $279.0 million in 2020, then tumbled by 57.67% to $118.1 million in 2021, then tumbled by 97.39% to $3.1 million in 2022, then skyrocketed by 4,983.70% to $156.8 million in 2023, then surged by 115.04% to $337.2 million in 2024.